OBJECTIVE: The purpose of this study is to investigate the dosimetric feasibility of delivering focal dose to multiparametric (mp) MRI-defined DILs in CT-based high-dose-rate (HDR) prostate brachytherapy with MR/CT registration and estimate its clinical benefit. METHODS: We retrospectively investigated a total of 17 patients with mp-MRI and CT images acquired pre-treatment and treated by HDR prostate brachytherapy. 21 dominant intraprostatic lesions (DILs) were contoured on mp-MRI and propagated to CT images using a deformable image registration method. A boost plan was created for each patient and optimized on the original needle pattern. In addition, separate plans were generated using a virtually implanted needle around the DIL to mimic mp-MRI guided needle placement. DIL dose coverage and organ-at-rick (OAR) sparing were compared with original plan results. Tumor control probability (TCP) was estimated to further evaluate the clinical impact on the boost plans. RESULTS: Overall, optimized boost plans significantly escalated dose to DILs while meeting OAR constraints. The addition of mp-MRI guided virtual needles facilitate increased coverage of DIL volumes, achieving a V150 > 90% in 85 % of DILs compared with 57 % of boost plan without an additional needle. Compared with original plan, TCP models estimated improvement in DIL control by 28 % for patients with external-beam treatment and by 8 % for monotherapy patients. CONCLUSION: With MR/CT registration, the proposed mp-MRI guided DIL boost in CT-based HDR brachytherapy is feasible without violating OAR constraints, and indicates significant clinical benefit in improving TCP of DIL. It may represent a strategy to personalize treatment delivery and improve tumor control. ADVANCES IN KNOWLEDGE: This study investigated the feasibility of mp-MRI guided DIL boost in HDR prostate brachytherapy with CT-based treatment planning, and estimated its clinical impact by TCP and NTCP estimation.
OBJECTIVE: The purpose of this study is to investigate the dosimetric feasibility of delivering focal dose to multiparametric (mp) MRI-defined DILs in CT-based high-dose-rate (HDR) prostate brachytherapy with MR/CT registration and estimate its clinical benefit. METHODS: We retrospectively investigated a total of 17 patients with mp-MRI and CT images acquired pre-treatment and treated by HDR prostate brachytherapy. 21 dominant intraprostatic lesions (DILs) were contoured on mp-MRI and propagated to CT images using a deformable image registration method. A boost plan was created for each patient and optimized on the original needle pattern. In addition, separate plans were generated using a virtually implanted needle around the DIL to mimic mp-MRI guided needle placement. DIL dose coverage and organ-at-rick (OAR) sparing were compared with original plan results. Tumor control probability (TCP) was estimated to further evaluate the clinical impact on the boost plans. RESULTS: Overall, optimized boost plans significantly escalated dose to DILs while meeting OAR constraints. The addition of mp-MRI guided virtual needles facilitate increased coverage of DIL volumes, achieving a V150 > 90% in 85 % of DILs compared with 57 % of boost plan without an additional needle. Compared with original plan, TCP models estimated improvement in DIL control by 28 % for patients with external-beam treatment and by 8 % for monotherapy patients. CONCLUSION: With MR/CT registration, the proposed mp-MRI guided DIL boost in CT-based HDR brachytherapy is feasible without violating OAR constraints, and indicates significant clinical benefit in improving TCP of DIL. It may represent a strategy to personalize treatment delivery and improve tumor control. ADVANCES IN KNOWLEDGE: This study investigated the feasibility of mp-MRI guided DIL boost in HDR prostate brachytherapy with CT-based treatment planning, and estimated its clinical impact by TCP and NTCP estimation.
Authors: Matthew Schmid; Juanita M Crook; Deidre Batchelar; Cynthia Araujo; David Petrik; David Kim; Ross Halperin Journal: Brachytherapy Date: 2012-04-17 Impact factor: 2.362
Authors: Louise J Murray; John Lilley; Christopher M Thompson; Vivian Cosgrove; Josh Mason; Jonathan Sykes; Kevin Franks; David Sebag-Montefiore; Ann M Henry Journal: Int J Radiat Oncol Biol Phys Date: 2014-03-28 Impact factor: 7.038
Authors: Constantinos Zamboglou; Benedikt Thomann; Khodor Koubar; Peter Bronsert; Tobias Krauss; Hans C Rischke; Ilias Sachpazidis; Vanessa Drendel; Nasr Salman; Kathrin Reichel; Cordula A Jilg; Martin Werner; Philipp T Meyer; Michael Bock; Dimos Baltas; Anca L Grosu Journal: Radiat Oncol Date: 2018-05-02 Impact factor: 3.481
Authors: Christopher H Chapman; Steve E Braunstein; Jean Pouliot; Susan M Noworolski; Vivian Weinberg; Adam Cunha; John Kurhanewicz; Alexander R Gottschalk; Mack Iii Roach; I-Chow Hsu Journal: J Contemp Brachytherapy Date: 2018-06-29
Authors: Luke A Matkovic; Tonghe Wang; Yang Lei; Oladunni O Akin-Akintayo; Olayinka A Abiodun Ojo; Akinyemi A Akintayo; Justin Roper; Jeffery D Bradley; Tian Liu; David M Schuster; Xiaofeng Yang Journal: Phys Med Biol Date: 2021-12-07 Impact factor: 3.609
Authors: Zachary A Eidex; Tonghe Wang; Yang Lei; Marian Axente; Oladunni O Akin-Akintayo; Olayinka A Abiodun Ojo; Akinyemi A Akintayo; Justin Roper; Jeffery D Bradley; Tian Liu; David M Schuster; Xiaofeng Yang Journal: Med Phys Date: 2022-05-17 Impact factor: 4.506
Authors: Yupei Zhang; Yang Lei; Richard L J Qiu; Tonghe Wang; Hesheng Wang; Ashesh B Jani; Walter J Curran; Pretesh Patel; Tian Liu; Xiaofeng Yang Journal: Med Phys Date: 2020-04-03 Impact factor: 4.071
Authors: Christopher W Smith; Ryan Alfano; Douglas Hoover; Kathleen Surry; David D'Souza; Jonathan Thiessen; Irina Rachinsky; John Butler; Jose A Gomez; Mena Gaed; Madeleine Moussa; Joseph Chin; Stephen Pautler; Glenn S Bauman; Aaron D Ward Journal: Phys Imaging Radiat Oncol Date: 2021-07-30